Download PDF
Hamostaseologie 2002; 22(04): 149-153
DOI: 10.1055/s-0037-1619557
Research Articles
Schattauer GmbH

Behandlung der oberflächlichen Thrombophlebitis

Treatment of superficial thrombophlebitis
W. Raake
1   Sankyo Pharma GmbH, München
,
M. Binder
1   Sankyo Pharma GmbH, München
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die oberflächliche Thrombophlebitis ist eine häufige Erkrankung, von der Frauen aufgrund ihrer Risikofaktoren stärker betroffen sind als Männer. Diagnostisch sollte eine eventuell gleichzeitig vorkommende tiefe Venenthrombose mit bildgebenden Verfahren abgegrenzt werden. In der Therapie sind Heparin bzw. niedermolekulare Heparine indiziert, wenn tiefe Venenthrombosen vorliegen bzw. ein Risiko hierfür besteht. Im akuten Stadium können nichtsteroidale Antiphlogistika oral genommen werden, um Schmerz und Entzündung zu lindern. Liegt gleichzeitig eine chronisch venöse Insuffizienz vor, unterstützen so genannte Ödemprotektiva (z.B. Rosskastaniensamenextrakt und flavonoidhaltige Präparate) die Behandlung.

Bei entzündlichen Veränderungen relativ kurzer oberflächlicher Venenabschnitte ohne Beteiligung des tiefen Venensystems ist die Beschränkung auf lokale Behandlungsmaßnahmen möglich. Neben der Kompressionstherapie sind mehrmalige tägliche Anwendungen heparin- und heparinoidhaltiger Salben bzw. Gele üblich.

Bewährt hat sich insbesondere die Anwendung von topischen Präparaten, die Mukopolysaccharidpolyschwefelsäureester (MPS) enthalten.

Die Problematik, die Wirksamkeit topischer Präparate bei der Behandlung der oberflächlichen Thrombophlebitis unter den gegenwärtig strengen Kautelen unserer Aufsichtsbehörde nachzuweisen und neue Produkte zu entwickeln, wird diskutiert.

Summary

Superficial thrombophlebitis is a frequently occurring disease which, because of risk factors, affects women to a greater extent than men. The presence of deep venous thrombosis should be excluded by imaging procedures. Heparin or low-molecular weight heparins are indicated for treatment, if deep venous thrombosis is present or threatening. In the acute stage non-steroidal antiinflammatory drugs can be taken orally in order to alleviate pain and inflammation. In the case of concomitant chronic venous insufficiency, edema protective drugs (e. g. preparations containing horse chestnut extract and flavonoids) can support the therapy. For the treatment of inflammatory conditions in relatively short superficial vein segments without involvement of the deep venous system, a limitation to topical treatment is possible. In addition to compression therapy, the application of creams or gels containing heparin or heparinoids are the usual treatment approach. The use of topical products containing mucopolysaccharide polysulfate (MPS) has been proven to be beneficial. The problem of providing evidence of the efficacy of topical products in the therapy for superficial thrombophlebitis under the current strict demands of our regulatory authorities and of developing new products under these conditions is discussed.

Schlüsselwörter

Thrombophlebitis - Heparin - Mukopolysaccharidpolyschwefelsäureester - topische Behandlung

Keywords

Thrombophlebitis - heparin - mucopolysaccharide polysulfate - topical treatment
 

  • Literatur

  • 1 Beatty J, Fitridge R, Benveniste G. et al. Acute superficial venous thrombophlebitis: does emergency surgery have a role?. Int Angiol 2002; 21: 93-5.
    PubMedGoogle Scholar
  • 2 Belcaro G, Nicolaides AN, Errichi BM. et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology 1999; 50: 523-9.
    CrossrefPubMedGoogle Scholar
  • 3 Blumenberg RM, Barton E, Gelfand ML. et al. Occult deep venous thrombosis complicating superficial thrombophlebitis. J Vasc Surg 1998; 27: 338-43.
    CrossrefPubMedGoogle Scholar
  • 4 Bounameaux H, Reber-Wasem MA. Superficial thrombophlebitis and deep vein thrombosis. A controversial association. Arch Intern Med 1997; 157: 1822-4.
    CrossrefPubMedGoogle Scholar
  • 5 Denzel C, Lang W. Die Diagnostik und Therapie der progressiven Thrombophlebitis epifaszialer Beinvenen. Zentralbl Chir 2001; 126: 374-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Diehm C, Trampisch HJ, Lange S. et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347: 292-4.
    CrossrefPubMedGoogle Scholar
  • 7 Downing LJ, Strieter RM, Kadell AM. et al. Low-dose-low-molecular-weight heparin is antiinflammatory during venous thrombosis. J Vasc Surg 1998; 28: 848-54.
    CrossrefPubMedGoogle Scholar
  • 8 Egg D. Effects of glycosamino-glycan-polysulfate and two non-steroidal anti-inflammatory drugs on prostaglandin E2 synthesis in Chinese hamster ovary cell cultures. Pharmacol Res Commun 1983; 15: 709-17.
    CrossrefPubMedGoogle Scholar
  • 9 Feied CF. Peripheral venous disease. In: Rosen P, Barkin RM. (eds). Emergency Medicine Principles and Practice. 4th ed. Mosby-Year Book; 1998
    Google Scholar
  • 10 Feied CF. Pulmonary embolism. In: Rosen P, Barkin RM. (eds). Emergency Medicine Principles and Practice. 4th ed. Mosby-Year Book; 1998
    Google Scholar
  • 11 Fenton JW, Ofosu FA, Brezniak DV. et al. Thrombin and antithrombotics. Semin Thromb Hemost 1998; 24: 87-91.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Görög P, Raake W. Antithrombotic effect of a mucopolysaccharide polysulfate after systemic, topical and percutaneous application. Arzneim Forsch (Drug Res) 1987; 37: 342-5.
    PubMedGoogle Scholar
  • 13 Hästbacka J, Tammisto T. Hirudoid® ointment in the prevention of infusion thrombophlebitis. Nord Med 1967; 14: 444-5.
    PubMedGoogle Scholar
  • 14 Hoppensteadt DA, Fareed J, Raake P. et al. Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates. Thromb Res 2001; 103: 157-63.
    CrossrefPubMedGoogle Scholar
  • 15 Klöcking HP, Raake W. Enhancement of t-PA relase by mucopolysaccharide polysulfate. Thromb Res 1992; 66: 89-92.
    CrossrefPubMedGoogle Scholar
  • 16 Kowalsky BL, Budde R. Perkutane Heparinoidtherapie bei postoperativen Infusionsthrombophlebitiden (Klinischer Doppelblindversuch). Therapiewoche 1978; 28: 7260-3.
    PubMedGoogle Scholar
  • 17 Kurz X, Kahn SR, Abenhaim L. et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the veines task force. Int Angiol 1999; 18: 83-102.
    PubMedGoogle Scholar
  • 18 Lane DA, Michalski R, van Ross ME. et al. Comparison of heparin and a semi-synthetic heparin analogue. Br J Haematol 1977; 37: 239-45.
    CrossrefPubMedGoogle Scholar
  • 19 Lipecz J, Bihler K. Prevention and treatment of infusion thrombophlebitis with an organoheparinoid ointment. Med Welt 1969; 20: 1662-5.
    PubMedGoogle Scholar
  • 20 MacGregor IR. Stimulation of urokinase activity by the polysulphated glycosaminoglycan present in Hirudoid® . IRCS Med Sci 1986; 14: 687-8.
    PubMedGoogle Scholar
  • 21 Mehta PP, Sagar S, Kakkar VV. Treatment of superficial thrombophlebitis: A randomized, double-blind trial of heparinoid cream. Brit Med J 1975; 3: 614-6.
    CrossrefPubMedGoogle Scholar
  • 22 NN. Leitlinien Phlebologie. Diagnostik und Therapie der Thrombophlebitis superficialis. Hautarzt 1998; 10: 585-6.
    PubMedGoogle Scholar
  • 23 Petruzellis V, Troccoli T, Candiani C. et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency – a double-blind randomized, controlled study. Angiology 2002; 53: 257-63.
    CrossrefPubMedGoogle Scholar
  • 24 Schedel F, Hennemann B, Reindl P. Kontrollierte Studie zur Wirksamkeit einer externen Therapie bei oberflächennaher Thrombophlebitis. Fortschr Med 1977; 95: 1557-60.
    PubMedGoogle Scholar
  • 25 Scurr JH, Machin SJ, Baily-King S. et al. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet 2001; 357: 1485-9.
    CrossrefPubMedGoogle Scholar
  • 26 Stüttgen G, Panse P, Bauer E. Permeation of the human skin by heparin and mucopolysaccharide polysulfuric acid ester. Arzneim Forsch (Drug Res) 1990; 40: 484-9.
    PubMedGoogle Scholar
  • 27 Thomas DP, Lane DA, Michalski R. et al. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-2.
    PubMedGoogle Scholar
  • 28 Unno N, Mitsuoka H, Uchiyama T. et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins. Surg Today 2002; 32: 397-401.
    CrossrefPubMedGoogle Scholar
  • 29 Mukopolysaccharidpolyschwefelsäureester (MPSSE) zur topischen Anwendung. Bundesanzeiger; 22.04.1992.
    Google Scholar